Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices
Repligen (RGEN) has acquired a bioprocessing analytics portfolio from 908 Devices for $70 million in cash. The acquisition includes four desktop devices for Process Analytical Technology (PAT) applications: MAVERICK and MAVEN for real-time monitoring and control, REBEL for cell culture media analysis, and ZipChip for product quality characterization.
The strategic purchase strengthens Repligen's PAT portfolio, enabling comprehensive analytics solutions across the entire bioprocess workflow. The acquisition includes the transfer of 908's bioprocessing team to Repligen. Meanwhile, 908 Devices will maintain focus on its handheld device portfolio for health and safety applications.
This transaction represents a significant step in Repligen's strategy to support customers' increasing adoption of digitization technologies in production processes, particularly enhancing their capabilities in upstream and downstream analytics.
Repligen (RGEN) ha acquisito un portafoglio di analisi per bioprocessi da 908 Devices per 70 milioni di dollari in contanti. L'acquisizione include quattro dispositivi desktop per applicazioni di Tecnologia Analitica di Processo (PAT): MAVERICK e MAVEN per il monitoraggio e il controllo in tempo reale, REBEL per l'analisi dei mezzi di coltura cellulare e ZipChip per la caratterizzazione della qualità del prodotto.
Questo acquisto strategico rafforza il portafoglio PAT di Repligen, consentendo soluzioni analitiche complete lungo l'intero flusso di lavoro del bioprocesso. L'acquisizione comprende il trasferimento del team di bioprocessi di 908 a Repligen. Nel frattempo, 908 Devices continuerà a concentrarsi sul suo portafoglio di dispositivi portatili per applicazioni di salute e sicurezza.
Questa transazione rappresenta un passo significativo nella strategia di Repligen per supportare l'adozione crescente da parte dei clienti delle tecnologie di digitalizzazione nei processi produttivi, migliorando in particolare le loro capacità nelle analisi upstream e downstream.
Repligen (RGEN) ha adquirido un portafolio de análisis de bioprocesos de 908 Devices por 70 millones de dólares en efectivo. La adquisición incluye cuatro dispositivos de escritorio para aplicaciones de Tecnología Analítica de Proceso (PAT): MAVERICK y MAVEN para monitoreo y control en tiempo real, REBEL para el análisis de medios de cultivo celular y ZipChip para la caracterización de la calidad del producto.
Esta compra estratégica refuerza el portafolio PAT de Repligen, permitiendo soluciones analíticas completas a lo largo de todo el flujo de trabajo del bioproceso. La adquisición incluye la transferencia del equipo de bioprocesos de 908 a Repligen. Mientras tanto, 908 Devices mantendrá su enfoque en su portafolio de dispositivos portátiles para aplicaciones de salud y seguridad.
Esta transacción representa un paso significativo en la estrategia de Repligen para apoyar la creciente adopción de tecnologías de digitalización por parte de los clientes en los procesos de producción, mejorando especialmente sus capacidades en análisis upstream y downstream.
Repligen (RGEN)은 908 Devices로부터 7000만 달러에 바이오 프로세스 분석 포트폴리오를 인수했습니다. 이번 인수에는 프로세스 분석 기술(PAT) 애플리케이션을 위한 네 가지 데스크탑 장치가 포함됩니다: 실시간 모니터링 및 제어를 위한 MAVERICK 및 MAVEN, 세포 배양 매체 분석을 위한 REBEL, 제품 품질 특성을 위한 ZipChip입니다.
이 전략적 구매는 Repligen의 PAT 포트폴리오를 강화하여 전체 바이오 프로세스 워크플로우에 걸쳐 포괄적인 분석 솔루션을 제공할 수 있게 합니다. 이번 인수에는 908의 바이오 프로세스 팀이 Repligen으로 이전되는 것도 포함됩니다. 한편, 908 Devices는 건강 및 안전 애플리케이션을 위한 휴대용 장치 포트폴리오에 집중할 것입니다.
이번 거래는 Repligen의 전략에서 고객들이 생산 과정에서 디지털화 기술을 점점 더 채택하도록 지원하는 중요한 단계로, 특히 업스트림 및 다운스트림 분석 능력을 향상시키는 데 기여합니다.
Repligen (RGEN) a acquis un portefeuille d'analytique de bioprocédés de 908 Devices pour 70 millions de dollars en espèces. L'acquisition comprend quatre appareils de bureau pour des applications de Technologie Analytique de Processus (PAT) : MAVERICK et MAVEN pour la surveillance et le contrôle en temps réel, REBEL pour l'analyse des milieux de culture cellulaire et ZipChip pour la caractérisation de la qualité des produits.
Ce achat stratégique renforce le portefeuille PAT de Repligen, permettant des solutions analytiques complètes tout au long du flux de travail des bioprocédés. L'acquisition comprend le transfert de l'équipe de bioprocédés de 908 à Repligen. Pendant ce temps, 908 Devices continuera de se concentrer sur son portefeuille d'appareils portables pour les applications de santé et de sécurité.
Cette transaction représente une étape significative dans la stratégie de Repligen pour soutenir l'adoption croissante des technologies de numérisation par ses clients dans les processus de production, en améliorant en particulier leurs capacités en matière d'analytique en amont et en aval.
Repligen (RGEN) hat ein Bioprozess-Analyseportfolio von 908 Devices für 70 Millionen Dollar in bar erworben. Die Akquisition umfasst vier Desktop-Geräte für Anwendungen der Prozessanalytik (PAT): MAVERICK und MAVEN für die Überwachung und Steuerung in Echtzeit, REBEL für die Analyse von Zellkulturmedien und ZipChip zur Charakterisierung der Produktqualität.
Dieser strategische Kauf stärkt Repligens PAT-Portfolio und ermöglicht umfassende Analyselösungen über den gesamten Bioprozess-Workflow hinweg. Die Akquisition umfasst auch die Übertragung des Bioprozess-Teams von 908 zu Repligen. In der Zwischenzeit wird sich 908 Devices weiterhin auf sein Portfolio an tragbaren Geräten für Gesundheits- und Sicherheitsanwendungen konzentrieren.
Diese Transaktion stellt einen bedeutenden Schritt in Repligens Strategie dar, die zunehmende Akzeptanz von Digitalisierungstechnologien in den Produktionsprozessen der Kunden zu unterstützen, insbesondere durch die Verbesserung der Fähigkeiten in der upstream- und downstream-Analytik.
- Strategic acquisition of four commercialized PAT technologies for $70M
- Expansion of analytics capabilities across entire bioprocess workflow
- Acquisition includes transfer of specialized bioprocessing team
- Strengthens market position in bioprocess digitization solutions
- Significant cash outlay of $70M for acquisition
Insights
Repligen's $70 million cash acquisition of 908 Devices' bioprocessing analytics portfolio represents a strategic expansion of its PAT (Process Analytical Technology) capabilities. This transaction brings four complementary devices into Repligen's ecosystem - MAVERICK and MAVEN for real-time monitoring and control, REBEL for cell culture media analysis, and ZipChip for high-resolution sample separations.
The acquisition perfectly aligns with industry trends toward increased digitization and process optimization in biopharmaceutical manufacturing. For Repligen, this deal fills a critical gap by extending its analytics capabilities to upstream processes, creating a comprehensive end-to-end solution across the entire bioprocess workflow.
With biopharma companies increasingly embedding PAT technologies to reduce costs, improve yields, and maintain quality, Repligen is positioning itself as a more complete solutions provider. The all-cash transaction structure indicates management's confidence in generating near-term value from these assets while avoiding dilution.
For 908 Devices, this divestiture allows them to refocus on their handheld device portfolio for health and safety applications, potentially improving their strategic alignment. The $70 million transaction represents meaningful capital that could accelerate their core business development.
Portfolio includes PAT devices for real-time process monitoring, control and analysis
WALTHAM, Mass. and BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq: RGEN), a life sciences company focused on bioprocessing technology leadership, and 908 Devices Inc. (Nasdaq: MASS), a pioneer in purpose-built handheld and desktop devices for chemical analysis, announce that Repligen has purchased 908 Devices’ desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications. 908 Devices remains focused on the growth of its newly expanded handheld device portfolio for vital health and safety applications.
The addition of these desktop assets complements and strengthens Repligen’s differentiated PAT portfolio that provides its biopharmaceutical and CDMO customers with actionable insights to optimize development processes and improve manufacturing efficiencies. Products acquired from 908 Devices include MAVERICK and MAVEN for real-time monitoring and control of critical bioprocess parameters; REBEL, an at-line cell culture media analyzer; and ZipChip, a high-resolution sample separations device used in the characterization of product quality attributes.
Olivier Loeillot, President and Chief Executive Officer at Repligen said, “We are really excited to onboard the 908 bioprocessing team and the four differentiated upstream PAT technologies that are commercialized today. They are the perfect complement to our downstream analytics portfolio and will enable Repligen to further penetrate a broad set of modalities and offer analytics solutions across the entire bioprocess workflow. This asset acquisition is a true win-win for both organizations, and a significant step forward for Repligen as our customers increasingly embed digitization technologies in their production processes.”
“Repligen’s leadership in commercializing innovative solutions that advance bioprocessing is a great fit for our novel desktop devices and our bioprocessing team. I wish them continued success,” said Kevin J. Knopp, CEO and Co-founder, 908 Devices. “Going forward, 908 Devices will continue to advance chemical detection at the point of need with our handheld analytical devices in vital health and safety applications.”
Transaction Terms and Advisors
The purchase consideration is a payment of
Webcast Information
908 Devices will discuss the divestiture of its desktop assets on a conference call for its fourth quarter 2024 financial results before market open on Tuesday, March 4, 2025 at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. A webcast of the conference call can be accessed from the company’s Investor Relations website.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at www.repligen.com, and follow us on LinkedIn.
About 908 Devices
908 Devices is revolutionizing chemical analysis with its simple handheld and desktop devices, addressing life-altering applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in forensics, bioprocessing, pharma/biopharma, life science research and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of complementary analytical technologies, microfluidic sampling and separations, software automation, and machine learning. To learn more, visit 908devices.com.
Repligen Forward Looking Statements
This press release contains forward-looking statements, which are made pursuant to and in reliance upon the safe harbor provisions of the federal securities laws including the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained herein which do not describe historical facts, including, among others, any express or implied statements or guidance regarding the expected results of our purchase of the bioprocessing analytics portfolio from 908 Devices on Repligen’s future financial performance, expected synergies following such purchase, the expected performance of our business, customer adoption and demand of 908 Devices’ technologies, the expected expansion of Repligen’s product lines and modalities, are based on management’s current expectations and beliefs and are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others, our ability to integrate 908 Devices’ desktop portfolio and relevant personnel into our existing business and to achieve expected synergies; our ability to maintain or expand historical sales of 908 Devices’ desktop portfolio; our ability to accurately forecast the asset acquisition, related costs and allocation of the purchase price and other intangibles related to the transaction and other asset adjustments; our ability to forecast customer demand of the acquired assets, and other risks and uncertainties detailed in Repligen’s most recent Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K on file with the Securities and Exchange Commission (the Commission) as well as our upcoming Annual Report on form 10-K for the year ended December 31, 2024 and any subsequent filings made with the Commission, which are available at the Commission’s website at www.sec.gov. Actual results may differ materially from those Repligen contemplated by these forward-looking statements, which reflect management’s current views, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions, and are based only on information currently available to us. Repligen cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Repligen disclaims any obligation to update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
908 Devices Forward Looking Statements
This press release includes “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the Company’s future revenue and growth, statements relating to the transaction, including statements regarding the benefits of the transaction. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement. These risks include but are not limited to: our ability to implement successfully strategic initiatives; risks relating to our ability to achieve the anticipated benefits from the transaction; actions and initiatives taken by both current and potential competitors; as well as the effects of more general factors such as changes in general market, economic or political conditions or in legislation, regulation or public policy. Additional risks are outlined under “Risk Factors” and elsewhere in the Company’s filings with the Securities and Exchange Commission, including our annual report on Form 10-K and our quarterly reports on Form 10-Q which are available on the SEC's website at www.sec.gov. Additional information will be made available in our annual and quarterly reports and other filings that we make from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.
| Repligen Contact: Sondra S. Newman, Global Head of Investor Relations (781) 419-1881 investors@repligen.com | ||
| 908 Devices Media Contact Barbara Russo brusso@908devices.com | 908 Devices Investor Contact Carrie Mendivil IR@908devices.com | |
FAQ
What is the value of Repligen's (RGEN) acquisition of 908 Devices' bioprocessing portfolio?
Which PAT devices did Repligen (RGEN) acquire from 908 Devices?
How will the 908 Devices acquisition impact Repligen's (RGEN) bioprocessing capabilities?
What will 908 Devices focus on after selling its desktop portfolio to Repligen (RGEN)?
